Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(5): e10585.
Published online 2010 May 14. doi:  10.1371/journal.pone.0010585
PMCID: PMC2871052

LIGHT Induces Distinct Signals to Clear an AAV-Expressed Persistent Antigen in the Mouse Liver and to Induce Liver Inflammation

Derya Unutmaz, Editor



Infection with adeno-associated virus (AAV) vector with liver tropism leads to persistent expression of foreign antigens in the mouse liver, with no significant liver inflammation or pathology. This provides a model to investigate antigen persistence in the liver and strategies to modulate host immunity to reduce or clear the foreign antigen expressed from AAV vector in the liver.

Methods/Principal Findings

We showed that expressing LIGHT with an adenovirus vector (Ad) in mice with established AAV in the liver led to clearance of the AAV. Ad-LIGHT enhanced CD8 effector T cells in the liver, correlated with liver inflammation. LTβR-Ig proteins blocked Ad-LIGHT in clearing AAV. Interestingly, in LTβR-null mice, Ad-LIGHT still cleared AAV but caused no significant liver inflammation.


Our data suggest that LIGHT interaction with the LTβR plays a critical role in liver inflammation but is not required for LIGHT-mediated AAV clearance. These findings will shed light on developing novel immuno-therapeutics in treating people chronically infected with hepato-tropic viruses.


Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection leads to liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) [1]. Similar to HBV and HCV, adeno-associated virus (AAV) is able to establish a persistent viral infection in the liver [2]. The mechanism of these viruses to evade host T cell responses and persist in the liver is not clear. The functional impairment of T cells may contribute to persistent infection of AAV, as is observed in HBV and HCV infection in humans [3], [4].

LIGHT is a member of the TNF superfamily (TNFSF14) that interacts with the LTβR [5] and HVEM [6] receptors. Ectopic expression of LIGHT in the tumor induces a massive infiltration of T cells, correlated with expression of chemokines, adhesion molecules, and rejection of established tumors at local and distal sites [7]. Additionally, injection of an adenoviral vector expressing LIGHT (Ad-LIGHT) into tumor tissue leads to generation of tumor-specific CTL and rejection of both established and disseminated metastasizing tumor cells in the peripheral tissues of mice [8]. Stimulation of the HVEM pathway with LIGHT enhances co-stimulation of T cell activation [9]. By blocking the interaction of LIGHT with the LTβR or HVEM receptors, using a soluble HVEM-Fc or LTβR-Fc fusion protein, the allogenic T cell responses and host-specific CTL responses are significantly reduced [10], [11].

In the liver, LTβR is expressed on Kupffer cells and may be involved in the process of T cell tolerance induction [12]. Additionally, the LTβR is also expressed on hepatocytes, where it contributes to liver regeneration and liver homeostasis [13]. In transgenic mice expressing LTα-β blocking LTβR signaling reduced inflammation in the liver [14]. Since the LIGHT/LTβR-HVEM signaling pathway is involved in modulation of immune responses in the liver, we investigated their function in the liver to test whether we can induce immune activation to clear the AAV in the liver using adenovirus-mediated LIGHT expression in the liver.

Results and Discussion

Ad-LIGHT causes clearance of AAV genomes in the liver

We used AAV packaged with serotype 8, which is liver tropic in vivo [15], and the U1a promoter was used to drive the expression of GFP in transduced hepatocytes [16]. We demonstrated that AAV infection with persistent GFP expression in the liver was efficiently established for at least 3 months. Therefore, AAV-U1a-GFP established a persistent expression of GFP in the liver with no significant liver inflammation (Fig. 1 A/B and data not shown).

Figure 1
Ad-LIGHT causes clearance of AAV infection in the liver.

The LIGHT-LTβR signaling pathway in the liver is involved in recruiting immune cells to the liver and in liver growth regulation. In addition, LIGHT is a potent co-stimulator of T cells. We postulate that the T cell tolerance induced by hepatic infection of AAV-GFP may be reversed by ectopic expression of LIGHT in the liver. To test this hypothesis, we investigated whether we can induce immune activation to clear the AAV-GFP using adenovirus-mediated LIGHT [8] expression in the liver. First, we infected C57/BL6 mice with AAV-GFP through the portal vein. After 18–21 days, mice were injected with Ad-LIGHT, Ad-Ctrl vector, or PBS. At 3–8 weeks after adenovirus injection, GFP expression and AAV genome levels in the liver were determined. Ad-LIGHT, but not Ad-Ctrl vector, diminished GFP expression in the AAV-GFP expressing liver (Fig. 1C). AAV genomes in the liver were cleared, as determined by PCR (Fig. 1D). When the LTβR-Ig fusion protein was added to the treated mice, it blocked the ability of Ad-LIGHT to clear AAV (Fig. 1E). These data indicate that ectopic expression of LIGHT in the liver can lead to clearance of an established AAV infection via interaction with LTβR.

LIGHT-mediated clearance of AAV correlates with increased liver inflammation and CD8+ effector T cells in the liver

In LIGHT-treated mice, a significant level of liver injury was detected by ALT or intra-liver infiltration (Figure 2). Ad-Ctrl infected mice induced low levels of ALT. However, Ad-LIGHT infected mice induced a higher ALT level than Ad-Ctrl mice (Figure 2A). This is confirmed by an increase in the number of leukocytes present in the liver (Figure 2B) and by the total number of intra-hepatic leukocytes (Figure 2C). The ALT level returned to normal around 60 dpi in both Ad-LIGHT and Ad-Ctrl infected mice (data not shown).

Figure 2
Ad-LIGHT induces liver inflammation.

To determine the immune effector cells that were stimulated by LIGHT, leukocytes were isolated from the liver and the spleen for analysis. We observed no increase in the percentage of CD4+CD44+ T cells in the liver. In contrast, there was a significant increase in the percentage of CD8+CD44+ T cells in both the liver and spleen of mice injected with Ad-LIGHT when compared to Ad-Ctrl (data not shown). We stimulated splenocytes or liver leukocytes with anti-CD3. Interestingly, there was a significant increase in the percentage of IFN-γ+ CD8+ in both the liver (Figure 3) and spleen (data not shown). LIGHT did not enhance IFN-γ expression in CD4+ cells either from the liver or spleen (data not shown). This result is consistent with reports that LIGHT is a co-stimulator of CD8+ T cells and causes an increase in IFN-γ production [9], [17], and that OT-I CD8 T cells, when transferred into mice with persistent Ova expression from an AAV vector, express IFN-γ and induce liver injury via activation of Kupffer cells [18].

Figure 3
LIGHT increases CD8+ effector T cells in the liver.

LTβR is not required for AAV clearance but is critical for LIGHT-induced liver inflammation

To determine if LTβR is required for LIGHT mediated clearance of AAV and liver injury, we tested the effect of Ad-LIGHT in LTβR-null mice (Figure 4). Interestingly, Ad-LIGHT led to clearance of AAV in both wild type and mutant mice, suggesting that LTβR was not critically required for LIGHT-mediated AAV clearance (Fig. 4A). We also examined the liver injury and leukocyte infiltration. Ad-LIGHT infected wild type mice showed a higher ALT level and lymphocyte infiltration than control mice (Fig. 4B–4D). However, we observed no significant ALT induction or leukocyte infiltration into the liver of LTβR-null mice treated with Ad-LIGHT (Figure 4B–D). We conclude that the LTβR is required for LIGHT-mediated liver inflammation and injury, but a distinct signal is required for its AAV clearance activity.

Figure 4
Ad-LIGHT causes no liver injury but still clears AAV in LTβR −/− mice.

In summary, delivery of Ad-LIGHT in mice with a persistent AAV infection led to clearance of AAV from the liver, correlated with elevated CD8+ effector T cells and liver injury. LTβR-Ig proteins blocked its activity. However, the LTβR was only required for LIGHT-induced liver injury but not for LIGHT-mediated AAV clearance. Therefore, LIGHT mediates distinct signals to clear AAV vectors in the liver and to induce liver inflammation. LTβR-Ig proteins may block LIGHT interaction with both LTβR and other receptors such as HVEM. The interaction of LIGHT-HVEM induces co-stimulation of CD8+ T cell activation, production of IFN-γ, and modulation of T cell responses [9], [17]. Since we observed a significant increase in effector CD8+ T cells and IFN-γ in LIGHT treated mice, the interaction of LIGHT with HVEM likely contributes to clearance of the AAV in the liver. It has been reported that LIGHT binds to LTβR or HVEM via distinct domains [9]. Our data suggest that it is feasible to generate mutant LIGHT molecules that specifically lose interaction with LTβR as novel therapeutics that can clear liver-tropic virus without liver injury.

Materials and Methods


Male C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME), and LTβR-null mice were maintained at the DLAM facility at the University of North Carolina at Chapel Hill. The project has been reviewed and approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee (IACUC ID: 07-114.0-B, approved on 4/13/2009).

AAV and adenovirus vectors and mouse inoculations

A self-complementary adeno-associated virus vector serotype 8 (AAV8) was kindly provided by Dr. R. Jude Samulski (Chapel Hill, NC) and used for the construction of AAV vectors expressing eGFP under the control of the U1a promoter were constructed. The recombinant Ad5 (E1/E3-) adenoviral vector expressing β-galactosidase (Ad-Ctrl) and Ad-LIGHT were generated as described [8]. To inoculate mice, 1×1011 vp AAV were injected through the portal vein. For Ad vector injection, 3×1010 vp Ad- vectors were injected intravenously 2–3 weeks after AAV inoculation.


All conjugated mAb were purchased (BD Pharmingen). The JL-8 GFP antibody was from Clontech. Anti-CD3 mAB (BD Pharmingen) was used to stimulate T cells. LTβR-Ig was produced as described [19], [20]. Human control IgG was obtained from Biogen Inc. LTβR-Ig or Human IgG (200 ug/kg) was injected i.p. weekly for three weeks, once right before and twice after adenovirus injection in AAV infected mice.

PCR, Western blotting, ALT, and liver histopathology

Serum was isolated to measure ALT levels. DNA was isolated from ~10 mg of liver tissue using a Qiagen DNeasy kit. PCR primers of eGFP and p18 were used to quantify relative AAV genome. Protein was isolated from the liver for Western blot to detect eGFP. Liver sections were fixed in 10% formalin and paraffin sections were stained by H&E.

Cell isolation, stimulation and flow cytometry

Liver leukocytes were isolated as described [18]. Briefly, the liver tissue suspension was treated with ACK lysis buffer to remove red blood cells. The cells were re-suspended in 40% Percoll (SIGMA) containing IMDM/10% FBS, loaded onto a 70% Percoll layer, and centrifuged for 20 minutes at 3000 rpm. Cells were stained with antibodies for CD4, CD8 and CD44. For T cell activation, 1×105 spleen/LN cells were stimulated with 5 ug/ml anti-CD3 mAb for 18 h, then stained for CD4, CD8 and intracellular cytokine (IFN-γ and IL-2). Flow cytometry was performed on a CyAn FACS machine (Dako, Carpinteria, CA).


We thank Selena Barbour for technical support, Dr. R. Jude Samulski and Dr. Xiao Xiao for sharing AAV vectors and advice.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants from National Institutes of Health (NIH), AI076142, AA018009 (L.S.), CA115540 and DK58891 (Y.X.F.), and T32 AI007273 (M.L.W), and China MOST 0997141002 (L.S. and Y.X.F.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol. 2007;25:71–99. [PubMed]
2. Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther. 2007;15:792–800. [PubMed]
3. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood. 2004;104:969–977. [PubMed]
4. Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest. 2007;117:3958–3970. [PMC free article] [PubMed]
5. Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, et al. A lymphotoxin-beta-specific receptor. Science. 1994;264:707–710. [PubMed]
6. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest. 1998;102:1142–1151. [PMC free article] [PubMed]
7. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity. 1998;8:21–30. [PubMed]
8. Yu P, Lee Y, Wang Y, Liu X, Auh S, et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007;179:1960–1968. [PMC free article] [PubMed]
9. Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 2000;6:283–289. [PubMed]
10. Xu Y, Flies AS, Flies DB, Zhu G, Anand S, et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood. 2007;109:4097–4104. [PubMed]
11. Yu P, Lee Y, Liu W, Chin RK, Wang J, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004;5:141–149. [PubMed]
12. Lee CM, Knight B, Yeoh GC, Ramm GA, Olynyk JK. Lymphotoxin-beta production following bile duct ligation: possible role for Kupffer cells. J Gastroenterol Hepatol. 2005;20:1762–1768. [PubMed]
13. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol. 2005;175:1295–1300. [PubMed]
14. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009;16:295–308. [PubMed]
15. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8:1248–1254. [PubMed]
16. Bartlett JS, Sethna M, Ramamurthy L, Gowen SA, Samulski RJ, et al. Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci U S A. 1996;93:8852–8857. [PubMed]
17. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000;164:4105–4110. [PubMed]
18. Giannandrea M, Pierce RH, Crispe IN. Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice. Hepatology. 2009;49:2010–2020. [PMC free article] [PubMed]
19. Wu Q, Wang Y, Wang J, Hedgeman EO, Browning JL, et al. The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues. J Exp Med. 1999;190:629–638. [PMC free article] [PubMed]
20. Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol. 1997;159:3288–3298. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science